Skip to main content

Table 1 Demographic and clinical characteristics for all patients and by amyloid group

From: Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer’s disease

 

All (n = 111)

A- (n = 49)

A+ (n = 62)

P

Number of women/men

57/54

20/29

37/25

0.05

Age in years

65.0 (8.4)

61.4 (8.9)

67.8 (6.8)

< 0.01

Years of education

13.8 (3.6)

14.2 (3.4)

13.5 (3.7)

0.34

MMSE*

25.7 (4.1)

27.1 (3.0)

24.6 (4.4)

< 0.01

CDR-SOB*

3.3 (2.4)

2.6 (2.3)

3.9 (2.3)

< 0.01

APOE ε4*, n (%)

63 (57.8)

17 (35.4)

46 (75.4)

< 0.01

Clinical diagnosis

   

< 0.01

 Clinical non-AD

48 (43.2)

41 (83.7)

7 (11.3)

 

 Alzheimer’s clinical syndrome

63 (56.8)

8 (16.3)

55 (88.7)

 

Stage, n (%)

   

< 0.01

 SCD

11 (9.9)

9 (18.4)

2 (3.2)

 

 MCI

42 (37.8)

27 (55.1)

15 (24.2)

 

 Dementia

58 (52.3)

13 (26.5)

45 (72.6)

 

CSF Aβ42 pg/ml

777.3 (353.8)

1110.6 (231.1)

513.9 (154.8)

< 0.01

CSF T-tau pg/ml

500.2 (367.9)

336.9 (167.5)

629.2 (428.5)

< 0.01

CSF P-tau pg/ml

71.7 (39.9)

55.7 (22.3)

84.3 (46.0)

< 0.01

CSF nanoplaques, median (Q1;Q3)

15 (11.4; 21.6)

13.2 (10.8; 17.4)

18 (12; 24.6)

0.02

  1. Data are given as mean (standard deviation) and P values are for two-tailed t-tests (continous variables) or χ2-tests (categorical variables) comparing amyloid groups, unless otherwise indicated
  2. amyloid-β, AD Alzheimer’s disease, APOE apolipoprotein E, CDR-SOB Clinical Dementia Rating Scale Sum of Boxes, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, n number of patients, P-tau phosphorylated tau, Q quartile, SCD subjective cognitive decline, T-tau total tau
  3. *MMSE, n = 104; CDR-SOB, n = 108; APOE, n = 109, † P-value for Mann-Whitney U test